ADI Launches the Alzheimer’s Disease Atlas
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Highlights from the National Dementia Plan Pan Regional Workshop 2026
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
ADI calls for urgent extension to WHO Global Action Plan
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
Supporting brain health and early diagnoses through digital apps
ADI member Dementia Australia has developed an app to help support brain health and encourage more timely dementia diagnoses.
Prioritising dementia at the G7
As ADI prepares to attend the G7 summit in Hiroshima, Japan, DY Suharya writes about the journey of making dementia a priority at the G7 summit.
Positive global developments for National Dementia Plans
The month of March has marked significant progress in the development and implementation of National Dementia Plans (NDPs), with the #WhatsYourPlan campaign leading to the launch of plans in Uruguay and Armenia, bringing the total number of WHO Member States with NDPs to 41.
Changing the world of dementia care: Silverado Senior Living’s journey to ADI Accreditation
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
ADI members in the Caribbean call for urgent action on dementia
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
#WhatsYourPlan campaign results in 20 commitments to implement National Dementia Plans
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
The FDA sets priority review date for Lecanemab
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.